Landos Biopharma, Inc.

LABP

US5150692011

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 23/05/2024 BST			5-day change	1st Jan Change
22.93 ^USD	+0.58%		+3.24%	+526.50%

05-24	Landos Biopharma, Inc.(NasdaqCM:LABP) dropped from S&P TMI Index	CI
05-23	AbbVie Completes Acquisition of Landos Biopharma	MT

Dr. Raquel Hontecillas, the Chief Scientific Officer of Landos Biopharma, Inc. Is No Longer with the Company

April 06, 2022 at 09:20 pm

Effective April 5, 2022, Dr. Raquel Hontecillas, the Chief Scientific Officer of Landos Biopharma, Inc., is no longer with the Company.

Latest news about Landos Biopharma, Inc.

Landos Biopharma, Inc.(NasdaqCM:LABP) dropped from S&P TMI Index	05-23	CI
AbbVie Completes Acquisition of Landos Biopharma	05-23	MT
Landos Biopharma, Inc. Announces Board and Executive Changes	05-23	CI
Landos Biopharma, Inc.(NasdaqCM:LABP) dropped from NASDAQ Composite Index	05-22	CI
AbbVie Inc. completed the acquisition of Landos Biopharma, Inc. from a group of shareholders.	05-22	CI
Landos Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
North American Morning Briefing : Stocks Seen -2-	04-02	DJ
HC Wainwright Downgrades Landos Biopharma to Neutral From Buy	04-01	MT
Deals of the day-Mergers and acquisitions	03-25	RE
Sector Update: Health Care Stocks Decline Late Afternoon	03-25	MT
Top Midday Gainers	03-25	MT
Sector Update: Health Care Stocks Softer in Afternoon Trading	03-25	MT
AbbVie to Acquire Landos Biopharma For About $137.5 Million; Landos Shares Jump	03-25	MT
Landos Biopharma Shares Surge 178% on Takeover Deal With AbbVie	03-25	DJ
AbbVie in Deal to Acquire Landos Biopharma for $137.5 Million	03-25	DJ
AbbVie to Acquire Landos Biopharma for About $137.5 Million	03-25	MT
AbbVie to Acquire Landos Biopharma for About $137.5 Million	03-25	MT
AbbVie to buy Landos to expand pipeline of immunity-related illnesses	03-25	RE
AbbVie Inc. agreed to acquire Landos Biopharma, Inc. on March 24, 2024.	03-24	CI
Landos Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Landos Biopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-21	CI
Landos Biopharma, Inc. Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn?s and Colitis	11-21	CI
Landos Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Landos Biopharma to Present At the American College of Gastroenterology 2023 Annual Scientific Meeting	23/10/23	CI
Landos Biopharma, Inc. Announces Resignation of Patrick Truesdell as Principal Accounting Officer, Patrick Truesdell Remain with Company Until November 10, 2023	21/09/23	CI

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of novel, oral, once-daily therapeutics for patients with autoimmune diseases. It is engaged in the development of therapeutics that target novel pathways at the interface of immunity and metabolism. Its lead product candidate is NX-13, a novel, oral, gut-selective, NLRX1 agonist. It is developing NX-13 as a once-daily, oral treatment for ulcerative colitis (UC), and Crohn's disease (CD), that targets NOD-like receptor X1 (NLRX1), a mitochondria-associated receptor that has been associated with the modulation of inflammatory cytokines for UC and CD. NX-13 is designed to target NLRX1 and induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. It has several preclinical product candidates, including LABP-66, LABP-73 and LABP-69. LABP-73, an oral, small molecule NLRX1 agonist for the potential treatment of asthma and eosinophilic disorders.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LANDOS BIOPHARMA, INC.	+526.50%	71.68M
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+44.98%	40.47B
CELLTRION, INC.	-10.87%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B